Furthermore, lung cancer has one of the lowest 5-year survival rates among the five leading malignancy killers, second only to pancreatic tumor. However, in the usa, lung cancer receives just $1,200 of federal government funding per death, even though breast cancer receives a lot more than $27,000 per death, followed by $14,000 for prostate cancers and $6,500 for colon cancer. ‘There is a significant disconnect between the incredible morbidity and mortality due to lung cancer, weighed against other cancers, and the amount of funding provided for lung cancer research,’ stated Kalpalatha Guntupalli, MD, FCCP, President of the American University of Chest Physicians.Johnson & Johnson Pharmaceutical Analysis & Development, L.L.C., supported the SMSNA Scientific Working Group and the McCullough study. ALZA Corporation obtained rights to develop and commercialize dapoxetine under an contract among ALZA, Pharmaceutical Product Development, Inc., and its own subsidiary, GenuPro, Inc., in 2001 January. Under the agreement, ALZA acquired the right to develop and commercialize dapoxetine for urogenital indications, including premature ejaculation, on a worldwide basis. Johnson and ALZA & Johnson Pharmaceutical Research & Development, L.L.C., are developing dapoxetine and will seek approval from regulatory authorities around the global world. Dapoxetine is undergoing Stage III clinical evaluation currently. Following successful regulatory approval, dapoxetine will be marketed by Ortho-McNeil Pharmaceutical, Inc., in america, Janssen-Ortho Inc.